keyword
https://read.qxmd.com/read/35082620/a-case-of-triple-negative-breast-cancer-with-germline-pathogenic-variants-in-both-brca1-and-brca2
#1
Miyuki Kitahara, Yasuo Hozumi, Mitsuki Machinaga, Yuka Hayashi
We report a rare case of hereditary breast and ovarian cancer syndrome (HBOC) with pathogenic variants in both BRCA1 and BRCA2 . The patient was a 78-year-old woman who visited the hospital after noticing a lump in her left breast 6 months before, which gradually increased in size. According to her family history, her maternal aunt developed breast cancer in her 40s. On palpation, a 4-cm large mass was palpated in the upper outer part of the left breast. A needle biopsy revealed invasive ductal carcinoma of the breast, which was negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2...
September 2021: Case Reports in Oncology
https://read.qxmd.com/read/34721634/expression-of-pd-l1-and-brca1-in-triple-negative-breast-cancer-patients-and-relationship-with-clinicopathological-characteristics
#2
JOURNAL ARTICLE
Xianghua Huang, Xiangqian Wang, Hongyan Qian, Xiaoxia Jin, Guoqin Jiang
OBJECTIVE: To study the expression of programmed cell death ligand-1 (PD-L1) and breast cancer susceptibility gene 1 (BRCA1) in triple-negative breast cancer (TNBC) patients and analyze their relationship with clinicopathological characteristics. METHODS: 76 TNBC tissues were collected as the research object, while 60 adjacent tissues were used as controls. All patients underwent surgical treatment, and the expression of PD-L1 and BRCA1 in cancer tissues and adjacent tissues was detected by immunohistochemistry...
2021: Evidence-based Complementary and Alternative Medicine: ECAM
https://read.qxmd.com/read/34060485/eliminating-hypoxic-tumor-cells-improves-response-to-parp-inhibitors-in-homologous-recombination-deficient-cancer-models
#3
JOURNAL ARTICLE
Manal Mehibel, Yu Xu, Caiyun G Li, Eui Jung Moon, Kaushik N Thakkar, Anh N Diep, Ryan K Kim, Joshua D Bloomstein, Yiren Xiao, Julien Bacal, Joshua C Saldivar, Quynh-Thu Le, Karlene A Cimprich, Erinn B Rankin, Amato J Giaccia
Hypoxia, a hallmark feature of the tumor microenvironment, causes resistance to conventional chemotherapy, but was recently reported to synergize with poly(ADP-ribose) polymerase inhibitors (PARPis) in homologous recombination-proficient (HR-proficient) cells through suppression of HR. While this synergistic killing occurs under severe hypoxia (<0.5% oxygen), our study shows that moderate hypoxia (2% oxygen) instead promotes PARPi resistance in both HR-proficient and -deficient cancer cells. Mechanistically, we identify reduced ROS-induced DNA damage as the cause for the observed resistance...
June 1, 2021: Journal of Clinical Investigation
https://read.qxmd.com/read/33842374/case-report-coinheritance-of-germline-mutations-in-apc-and-brca1-in-colorectal-cancer
#4
Wei Huang, Jin Bian, Xiaoping Qian, Lin Shao, Haiyan Li, Lu Zhang, Lin Wang
Deleterious mutations in APC gene cause the autosomal dominant familial adenomatous polyposis (FAP) which is typically characterized by the occurrence of hundreds to thousands of colorectal adenomas that eventually lead to colorectal cancers (CRCs). BRCA1/2 are the two major susceptibility genes for breast and ovarian cancers. Here, we reported a coinheritance of mutations in APC and BRCA1 genes in a 20-year-old CRC patient with typical clinical features for FAP. Multiple relatives in the family of the patient were affected by colorectal and other cancers...
2021: Frontiers in Oncology
https://read.qxmd.com/read/33637776/bkm120-sensitizes-brca-proficient-triple-negative-breast-cancer-cells-to-olaparib-through-regulating-foxm1-and-exo1-expression
#5
JOURNAL ARTICLE
Yu Li, Yuantao Wang, Wanpeng Zhang, Xinchen Wang, Lu Chen, Shuping Wang
Poly (ADP-ribose) polymerase (PARP) inhibitors offer a significant clinical benefit for triple-negative breast cancers (TNBCs) with BRCA1/2 mutation. However, the narrow clinical indication limits the development of PARP inhibitors. Phosphoinositide 3-kinase (PI3K) inhibition sensitizes BRCA-proficient TNBC to PARP inhibition, which broadens the indication of PARP inhibitors. Previously researches have reported that PI3K inhibition induced the defect of homologous recombination (HR) mediated repair by downregulating the expression of BRCA1/2 and Rad51...
February 26, 2021: Scientific Reports
https://read.qxmd.com/read/32356124/case-report-analysis-of-brca1-and-brca2-gene-mutations-in-a-hereditary-ovarian-cancer-family
#6
JOURNAL ARTICLE
Ying Liao, Chunhua Tu, Xiaoxia Song, Liping Cai
OBJECTIVE: Breast cancer susceptibility gene 1/2 (BRCA1/2) is the most important susceptibility gene associated with hereditary ovarian cancer (HOC). We aimed to screen BRAC1 and BRAC2 gene mutations in a member of a hereditary ovarian cancer family in China, and to analyze the structure and function of the mutant protein. METHODS: A typical HOC family was selected. Blood samples and pathological tissue samples were taken from the female members of the family. Blood samples from two patients with sporadic ovaries of the same pathological type were taken as a control group...
April 30, 2020: Journal of Assisted Reproduction and Genetics
https://read.qxmd.com/read/32277283/characterization-of-therapy-related-acute-leukemia-in-hereditary-breast-ovarian-carcinoma-patients-role-of-brca1-mutation-and-topoisomerase-ii-directed-therapy
#7
JOURNAL ARTICLE
Bhausaheb Bagal, Rohit Kumar, Tarang Gaur, Vikas Talreja, Avinash Bonda, Nikhil Patkar, Dhanlaxmi Shetty, Pradnya Kowtal, P G Subramanian, Sudeep Gupta, Rajiv Sarin, Syed K Hasan
Therapy-related acute leukemias (t-ALs) represent approximately 10-20% of all acute leukemias, are frequently resistant to chemotherapy, and are associated with guarded outcomes. The national comprehensive cancer network data suggest that t-AL cases are diagnosed at increasing rates in breast cancer patients treated with chemotherapeutic agents targeting topoisomerase II. Two cases of BRCA1-mutated ovarian and breast carcinoma who developed therapy-related APL and ALL, respectively, following topoisomerase II-directed therapy were characterized...
April 10, 2020: Medical Oncology
https://read.qxmd.com/read/28442756/crystal-structure-based-discovery-of-a-novel-synthesized-parp1-inhibitor-ol-1-with-apoptosis-inducing-mechanisms-in-triple-negative-breast-cancer
#8
JOURNAL ARTICLE
Leilei Fu, Shuya Wang, Xuan Wang, Peiqi Wang, Yaxin Zheng, Dahong Yao, Mingrui Guo, Lan Zhang, Liang Ouyang
Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved enzyme focused on the self-repair of cellular DNA damage. Until now, numbers of PARP inhibitors have been reported and used for breast cancer therapy in recent years, especially in TNBC. However, developing a new type PARP inhibitor with distinctive skeleton is alternatively promising strategy for TNBC therapy. In this study, based on co-crystallization studies and pharmacophore-docking-based virtual screening, we discovered a series of dihydrodibenzo[b,e]-oxepin compounds as PARP1 inhibitors...
December 5, 2016: Scientific Reports
https://read.qxmd.com/read/27920426/crystal-structure-based-discovery-of-a-novel-synthesized-parp1-inhibitor-ol-1-with-apoptosis-inducing-mechanisms-in-triple-negative-breast-cancer
#9
JOURNAL ARTICLE
Leilei Fu, Shuya Wang, Xuan Wang, Peiqi Wang, Yaxin Zheng, Dahong Yao, Mingrui Guo, Lan Zhang, Liang Ouyang
Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved enzyme focused on the self-repair of cellular DNA damage. Until now, numbers of PARP inhibitors have been reported and used for breast cancer therapy in recent years, especially in TNBC. However, developing a new type PARP inhibitor with distinctive skeleton is alternatively promising strategy for TNBC therapy. In this study, based on co-crystallization studies and pharmacophore-docking-based virtual screening, we discovered a series of dihydrodibenzo[b,e]-oxepin compounds as PARP1 inhibitors...
December 2016: Scientific Reports
https://read.qxmd.com/read/9257197/vitamin-d3-analogs-and-their-24-oxo-metabolites-equally-inhibit-clonal-proliferation-of-a-variety-of-cancer-cells-but-have-differing-molecular-effects
#10
COMPARATIVE STUDY
M J Campbell, G S Reddy, H P Koeffler
The seco-steroid hormone, 1 alpha, 25 dihydroxyvitamin D3 (1 alpha,25(OH)2D3) binds to a specific nuclear receptor that acts as a ligand-inducible transcription factor. The resulting genomic effects include partial arrest in G0/G1 of the cell cycle and induction of differentiation; these effects have been observed in various types of cancer. Recently, we produced enzymatically the natural 24-oxo metabolites of 1 alpha,25(OH)2D3 and two of its potent synthetic analogs (1 alpha,25-(OH)2-16-ene-D3 and 1 alpha,25-(OH)2-20-epi-D3) using a rat kidney perfusion system...
September 1, 1997: Journal of Cellular Biochemistry
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.